GAA and hemophilia A: One could speculate that such a fusion protein may have clinical utility in the case of autoimmune disorders with a well-characterized antigen or in the case of immunogenic therapeutic protein product (i.e., FVIII for hemophilia A or recombinant acid-alpha glucosidase (rGAA) for Pompe’s disease) as the target.